MRKR Stock — Marker Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s Multi Antigen Recognizing (“MAR”)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.95

Market cap

$15.8M

Cash

$11.3M

Enterprise value

$4.5M

Balance sheet

Cash	$11.3M
Debt	$0.0M
Net cash	$11.3M
Enterprise value	$4.5M
Basic shares	16.7M shares
Fully diluted shares	26.1M shares
Fully diluted market cap	$24.8M
Cash per share	$0.68
Quarterly burn	$3.7M
Cash runway	3.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.

Share structure

Common

16.7M

Pre-funded warrants

2.6M

Options

1.8M

RSUs

0.0M

Warrants

5.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

26.1M

Cap table as of 2026-06-30.

Price history

Loading MRKR daily closes…

Loading price history…

Next catalyst

MT-601 · Apr 10 - May 22 in 17 mo · Phase 1 · Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 10 - May 22 in 17 mo	MT-601	Phase 1	Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed	—
Aug 27 - Oct 8 in 22 mo	MT-601 dose 200 million cells	Phase 1	Pancreas Cancer; Pancreatic Cancer Metastatic; Pancreatic Cancer (Unresectable)	—
Oct 13 - Nov 24 in 36 mo	MT-401-OTS	Phase 1	Acute Myeloid Leukemia, in Relapse; MDS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MT-601

Phase 1 · Active Modality: cell therapy (autologous multi-antigen-recognizing MAR-T cells, non-genetically engineered)

Target NY-ESO-1 / PRAME / MAGE-A4 / Survivin / WT1 / SSX2

Partnerships Baylor College of Medicine (BCM): exclusive license to MAR-T technology ($5M equity; up to $64.85M milestones; tiered royalties). Grants: CPRIT $13.1M (AML, now shifted), CPRIT $9.5M (pancreatic), NIH SBIR $2M (NHL) + $2M (pancreatic PANACEA), FDA Orphan grant $2M, DoW $4.2M (LBCL, Jul 2026)

Indications

Lymphoma (B-cell, relapsed after anti-CD19 CAR-T or CAR-T ineligible) (Phase 1)
Pancreatic cancer (metastatic) (Phase 1)

Catalysts

— 2026

Status note Lead program. Phase 1 APOLLO in lymphoma: 24 patients (15 NHL, 9 HL) with objective responses and favorable safety (update Aug 2025, cutoff Jun 2025). Technology-transfer/manufacturing SOW with Cellipont signed Jun 2025 for pivotal-trial scale-up.

MT-401-OTS

Phase 1 · Active Modality: cell therapy (off-the-shelf MAR-T cells)

Aliases MT-401

Target WT1 / NY-ESO-1 / PRAME / Survivin

Partnerships BCM license (as MT-601); CPRIT/FDA/NIH grants agreed to shift funds to MT-401-OTS

Indications

Acute myeloid leukemia (AML, post-transplant / post-HMA) (Phase 1)
Myelodysplastic syndromes (MDS) (Stage not disclosed)

Status note Off-the-shelf MAR-T program; funders (CPRIT $13.1M, FDA Orphan $2M, NIH SBIR $2M) shifted support from MT-401 to MT-401-OTS.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MT-601
Lead indication	Non-Hodgkin Lymphoma, Adult
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05798897	Phase 1	Recruiting	Sponsor	MRKR	—	Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed	—
NCT06549751	Phase 1	Not yet recruiting	Sponsor	MRKR	—	Pancreas Cancer; Pancreatic Cancer Metastatic; Pancreatic Cancer (Unresectable)	—
NCT06552416	Phase 1	Recruiting	Sponsor	MRKR	—	Acute Myeloid Leukemia, in Relapse; MDS	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Marker Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Aisling Capital	325,370	no change	0.10%	2026-08-13

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

MRKR — Marker Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

MRKR — Marker Therapeutics Inc.